JRoon71
5 minutes ago
Fortunately for Amarin (and investors), there will always be fat, sick, diseased individuals, no matter how many drugs get rolled out.
I think one of the biggest challenges for Vascepa is that it is not an "acute" treatment, like most drugs that impact heart, diabetes, weight, etc. (s
budfoxfun
9 minutes ago
"Our technology is powerful, safe, cost-effective, and applicable to various sectors such as agriculture, waste management, soil remediation, and more. With our global patents and pending patents, we are revolutionizing environmental solutions for a sustainable future."
duelittle2
10 minutes ago
Outstanding Shares
2,377,055,317
11/18/2024
Outstanding Shares
2,377,055,317
11/11/2024
Outstanding Shares
2,162,927,317
11/04/2024
Outstanding Shares
2,162,927,317
10/28/24
Ou